(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 February 2012 (23.02.2012)

PCT

(10) International Publication Number
WO 2012/024666 A2

(51) International Patent Classification:
C12N 5/0783 (2010.01) *A61K 35/12* (2006.01)

(21) International Application Number:
PCT/US2011/048578

(22) International Filing Date:
22 August 2011 (22.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/401,881 20 August 2010 (20.08.2010) US
61/495,055 9 June 2011 (09.06.2011) US

(71) Applicant *(for all designated States except US)*: **IMMUNOVATIVE THERAPIES, LTD.** [IL/IL]; POB 974, 60850 Shoham (IL).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **HAR-NOY, Michael** [US/IL]; 22-1 Emek Zebulun, 71700 Modiin (IL).

(74) Agents: **BRUSH, David, D.** et al.; Westman, Champlin & Kelly, P.A., 900 Second Avenue South, Suite 1400, Minneapolis, MN 55402-3319 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title**: CELLS EXPRESSING TH1 CHARACTERISTICS AND CYTOLYTIC PROPERTIES




FIG. 1A




FIG. 1B

(57) **Abstract**: A novel cell type has been generated that has both Thl characteristics and cytolytic activity. These Thl/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Thl characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Thl/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Thl/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T- cells to form Thl/killer cells and administering these Thl/killer cells with the cytolytic activity to a patient wherein theThl/killer cells are allogeneic to the patient.

WO 2012/024666 A2